Featured

Featured Videos

At the conclusion of the ASGCT meeting, Julianna LeMieux, PhD, GEN’s deputy editor in chief, and Corinna Singleman, PhD, GEN’s managing editor, chat about how they spent their time at the conference and their unique takeaways from the research and news presented through the week.
They discussed general insights on how diverse the topics have been. Julianna discussed David Liu’s, PhD, keynote on Wednesday and Corinna shared about an interview she had with Frederic Revah, PhD, Genethon.

Bye, Bye, Baltimore: GEN’s Takeaways from ASGCT

The American Society of Gene and Cell Therapy (ASGCT) meeting is off and running in Baltimore, Maryland. Kevin Davies, PhD, editorial director and Corinna Singleman, PhD, managing editor at GEN are on the ground—in the talks, expo hall, and press room, covering as much of the news as they can. 
Here, they take a moment to chat about the start of the meeting and what they are looking forward to over the next few days. Davies discusses how this year’s conference is different from the meetings five years ago, opening workshops featuring Y. Esther Tak, PhD, Arena Bioworks, Samagya Banskota, PhD, Boston University, Jonathan Levy, PhD, Prime Medicine, Makoto Saito, PhD, Broad Institute, and Cameron Glasscock, PhD, University of Washington. They both share their thoughts on an interview with Mammoth’s CSO Lucas Harrington, and the news about the DAYLIGHT trial. Singleman shares her first impressions of ASGCT as a first-time attendee, some interesting talks during the “Prospects for Prenatal Gene and Cell Therapy” session Tuesday morning, and how things are going in the exhibition hall. 

ASGCT 2024: A Video Update from Baltimore

Endpoints: Critical Preclinical Markers in Neurodegeneration Disease Assays

In this GEN webinar, our speaker John Renger, PhD, CSO at Cerevel Therapeutics, discusses preclinical markers used in assays relevant to neurodegenerative disease processes, including the evaluation of autophagy and mitophagy using methods such as immunohistochemistry, western blotting, ELISA-like assays, high content analysis, and other platforms.
GEN May 2024 magazine cover

The May issue of GEN has a hidden theme: technologies are emerging to shore up our immune defenses. What’s so hidden about that? Well, the technologies are quite varied: multispecific antibodies, cell therapies, and next-generation vaccines. So, it’s easy to miss the big picture, which is that the immune system is both intricate and finely balanced—as deserving, in its own way, of the respect accorded celestial mechanics, the subtleties of which inspired the ancients to coin the term musica universalis, which refers to the unheard music of harmony and equilibrium. Now it’s the immune system’s turn. Should the immune system become discordant or disequilibrated by the operations of a disease process, it needn’t succumb to chaos. Interventions are possible. For example, when cancer intrudes, therapeutic cells can restore order. If only rogue planets could be so easily counterbalanced.